Dr. Patrick Borgen on Breast Cancer Becoming More a Medical Disease Than Surgical
Patrick Borgen, MD, says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, talks about how breast cancer is becoming less of a surgical disease and more of a medical disease. Borgen says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.
Borgen says the sequence for treating breast cancer has shifted as well. The sequence has historically been surgery, therapy and then radiation, though more and more patients are starting with treatment. Borgen says these treatments are capable of sterilizing the disease and, alongside medical professionals’ greater understanding of the disease, treatment has become better over the years.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
